ArticleDiabetes2018
A Global Overview of Precision Medicine in Type 2 Diabetes.
Article in Diabetes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic models for all-cause and cardiovascular mortality in type 2 diabetes: Systematic review.Diabetic medicine : a journal of the British Diabetic Association · 2026Pooled it
- Decision models of prediabetes populations: A systematic review.Diabetes, obesity & metabolism · 2019Pooled it
- Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology.Nature metabolism · 2024Trial
- Interactions between nutrition and the epigenome: how can it be harnessed for public health?Future science OA · 2026Article
- Metabolomics in precision medicine: Application and prospect in cancer research.Journal of food and drug analysis · 2026Review
- Exploring Treatment Paradigms in Type 2 Diabetes: A Comparison of Independent and Combined Therapeutic Approaches.Cureus · 2026Review
- Mussel-Bioinspired Edible CaAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- pH-responsive hyaluronic acid-RSC advances · 2026Article
- Precision Nursing: The Personalized Future of Care and Revolution in Clinical Practice.Revista brasileira de enfermagem · 2026Article
- Foodomics in Diabetes Management: A New Approach.Food science & nutrition · 2025Review
- Association of Calpain-10 gene polymorphisms with Type 2 diabetes mellitus: a case-control study from a tertiary care hospital in Pakistan.BMC medical genomics · 2025Article
- Data-driven Cluster Analysis Reveals Increased Risk for Severe Insulin-deficient Diabetes in Black/African Americans.The Journal of clinical endocrinology and metabolism · 2025Article
- New approach to optimize therapy in type 2 diabetes mellitus: the importance of subclassification.Frontiers in endocrinology · 2025Review
- Explainable Prediction of Long-Term Glycated Hemoglobin Response Change in Finnish Patients with Type 2 Diabetes Following Drug Initiation Using Evidence-Based Machine Learning Approaches.Clinical epidemiology · 2025Article
- pH-Sensitive Hydrogels Fabricated with Hyaluronic Acid as a Polymer for Site-Specific Delivery of Mesalamine.ACS omega · 2024Article
- Transform diabetes care with precision medicine.Health science reports · 2023Review
- Using Continuous Glucose Monitoring to Prescribe a Time to Exercise for Individuals with Type 2 Diabetes.Journal of clinical medicine · 2023Article
- Precision Medicine in Type 1 Diabetes.Journal of the Indian Institute of Science · 2023Review
- A novel diabetes typology: towards precision diabetology from pathogenesis to treatment.Diabetologia · 2022Review
- Characterization of data-driven clusters in diabetes-free adults and their utility for risk stratification of type 2 diabetes.BMC medicine · 2022Article
Corrections and comments
- Commented on byIn This Issue of2018
Authors and funding
4 authors.
Funding
Abstract
The detailed characterization of human biology and behaviors is now possible at scale owing to innovations in biomarkers, bioimaging, and wearable technologies; "big data" from electronic medical records, health insurance databases, and other platforms becoming increasingly accessible; and rapidly evolving computational power and bioinformatics methods. Collectively, these advances are creating unprecedented opportunities to better understand diabetes and many other complex traits. Identifying hidden structures within these complex data sets and linking these structures to outcome data may yield unique insights into the risk factors and natural history of diabetes, which in turn may help optimize the prevention and management of the disease. This emerging area is broadly termed "precision medicine." In this Perspective, we give an overview of the evidence and barriers to the development and implementation of precision medicine in type 2 diabetes. We also discuss recently presented paradigms through which complex data might enhance our understanding of diabetes and ultimately our ability to tackle the disease more effectively than ever before.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.